08 January 2025
08 January 2025
Candid plans to conduct first-in-human studies in 2026 as it continues its T-cell engager deal drive.
Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).
The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
The decision is backed by data from the randomised multi-centre Phase II ARTEMIS-002 trial.
The therapy is being assessed in a randomised Phase II trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
